Developer docs
API playgroundTry for free, no card

Search company profiles

Kali-Extracts

Full company profile

uuid0006rx9

Namestring
Kali-Extracts
Company typeenum
Private
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cannabis extraction, biopharmaceutical technology, cannabis therapeutics, phytocannabinoid processing, cannabis derivatives
Industry2 codes
PRIMARYAFAJAKAD
Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Spice and Extract Manufacturing311942
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cannabis Biopharmaceuticals
Social media profiles1 record
Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kali-Extracts describes itself as a cannabis biopharmaceutical technology company. Beyond that self-description, no specific products, services, extraction processes, formulations, or therapeutic candidates are disclosed in the source data. The company website has been compromised and contains only default WordPress placeholder content, so the actual product/service portfolio cannot be detailed.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information is available. The website content consists primarily of default WordPress placeholder pages (a "Sample Page" with generic content and a "Hello world!" blog post) and navigation elements (Blog, About, FAQs, Authors, Events, Shop, Patterns, Themes). No actual products, services, or business offerings are described.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

US-focused CBD wellness and botanical extract brand; comparable on extract product format and consumer/wellness channel, though private and not biopharmaceutical.

TypeBroad incumbent
Description

Large-scale Canadian licensed producer active in medical cannabis and cannabinoid derivatives; comparable in cannabis therapeutics category but at significantly larger scale.

TypeDirect peer
Description

US-based publicly traded hemp-derived CBD and cannabis wellness company trading on OTC markets, very close comparability to Kali-Extracts in scale, listing tier, and product category.

TypeDirect peer
Description

Vertically integrated hemp-derived CBD wellness brand with botanical extract focus; comparable product format (botanical extracts) and consumer-adjacent regulatory positioning.

TypeBroad incumbent
Description

Public cannabis operator with a strategic focus on cannabinoid science and product innovation including fermentation-derived cannabinoids; comparable biopharmaceutical-adjacent cannabis exposure.

TypeDirect peer
Description

Pioneer in cannabinoid-derived prescription pharmaceuticals (Epidiolex); represents the cannabis biopharmaceutical reference outcome that a company like Kali-Extracts would aspire to in product/market terms.

TypeBroad incumbent
Description

Major diversified cannabis company with cannabinoid-based wellness and pharmaceutical initiatives; broad incumbent in the same overall botanical/therapeutic cannabis space.

8Tilray Brands
TypeBroad incumbent
Description

Large multi-jurisdiction cannabis operator with a growing pharmaceutical and extraction business; comparable on botanical extraction and cannabis therapeutics, but materially larger scale.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kali-Extracts

Cannabis Biopharmaceuticalskali-extracts.com

Kali-Extracts firmographics

Firmographics
Name
Kali-Extracts
Website
https://kali-extracts.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Kali-Extracts industry classification

Industry
Product category
Cannabis Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Spice and Extract Manufacturing (311942)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYAFAJAKAD
Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Cannabis extraction
  • Biopharmaceutical technology
  • Cannabis therapeutics
  • Phytocannabinoid processing
  • Cannabis derivatives

Where Kali-Extracts is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Markets served

Kali-Extracts business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Kali-Extracts product offering

Product offering

Core offering

Kali-Extracts describes itself as a cannabis biopharmaceutical technology company. Beyond that self-description, no specific products, services, extraction processes, formulations, or therapeutic candidates are disclosed in the source data. The company website has been compromised and contains only default WordPress placeholder content, so the actual product/service portfolio cannot be detailed.

Product overview

No product or service information is available. The website content consists primarily of default WordPress placeholder pages (a "Sample Page" with generic content and a "Hello world!" blog post) and navigation elements (Blog, About, FAQs, Authors, Events, Shop, Patterns, Themes). No actual products, services, or business offerings are described.

Differentiator

Problem solved

Functional benefit

Companies that use Kali-Extracts

Customer profile

Ideal customer profiles1 record

Kali-Extracts technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Kali-Extracts partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Kali-Extracts competitors and assessment

Company assessment

Emerging players

  • CBDfx: US-focused CBD wellness and botanical extract brand; comparable on extract product format and consumer/wellness channel, though private and not biopharmaceutical.

Broad incumbents

  • Aurora Cannabis: Large-scale Canadian licensed producer active in medical cannabis and cannabinoid derivatives; comparable in cannabis therapeutics category but at significantly larger scale.
  • Cronos Group: Public cannabis operator with a strategic focus on cannabinoid science and product innovation including fermentation-derived cannabinoids; comparable biopharmaceutical-adjacent cannabis exposure.
  • Canopy Growth Corporation: Major diversified cannabis company with cannabinoid-based wellness and pharmaceutical initiatives; broad incumbent in the same overall botanical/therapeutic cannabis space.
  • Tilray Brands: Large multi-jurisdiction cannabis operator with a growing pharmaceutical and extraction business; comparable on botanical extraction and cannabis therapeutics, but materially larger scale.

Direct peers

  • Medical Marijuana Inc: US-based publicly traded hemp-derived CBD and cannabis wellness company trading on OTC markets, very close comparability to Kali-Extracts in scale, listing tier, and product category.
  • Charlotte's Web Holdings: Vertically integrated hemp-derived CBD wellness brand with botanical extract focus; comparable product format (botanical extracts) and consumer-adjacent regulatory positioning.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in cannabinoid-derived prescription pharmaceuticals (Epidiolex); represents the cannabis biopharmaceutical reference outcome that a company like Kali-Extracts would aspire to in product/market terms.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

Kali-Extracts social profiles

Digital presence

Kali-Extracts financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kali-Extracts leadership team

Management profile

Number of profiles

Profiles1 record

Kali-Extracts funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kali-Extracts M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kali-Extracts

What does Kali-Extracts do?

Kali-Extracts describes itself as a cannabis biopharmaceutical technology company. Beyond that self-description, no specific products, services, extraction processes, formulations, or therapeutic candidates are disclosed in the source data. The company website has been compromised and contains only default WordPress placeholder content, so the actual product/service portfolio cannot be detailed.

When was Kali-Extracts founded?

Kali-Extracts was founded in 2006. It employs 101 to 250 people.

Where is Kali-Extracts based?

Kali-Extracts is headquartered in Dallas, United States, in the North America region.

Who are Kali-Extracts's main competitors?

CBDfx is listed as an emerging player. Broad incumbents are Aurora Cannabis, Cronos Group, Canopy Growth Corporation and Tilray Brands. Direct peers are Medical Marijuana Inc, Charlotte's Web Holdings and GW Pharmaceuticals (Jazz Pharmaceuticals).

Does Kali-Extracts have an API?

No public API is recorded for Kali-Extracts.

What industry is Kali-Extracts in?

Kali-Extracts's product category is Cannabis Biopharmaceuticals. Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts), with a secondary code of CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePAOG 2021 CBD Nutraceuticals Sales Plan Preview This Friday To Include ALKM and USMJ Partnership HighlightsPAO Group, Inc. announced that its CBD Nutraceutical Sales Rollout Presentation on May 7, 2021, will highlight the roles of Alkame Holdings and North American Cannabis Holdings in its CBD nutraceutical product line. The company acquired RespRx, a CBD treatment for COPD derived from a patented cannabis extraction method, from Kali-Extracts, and is working with contract research organization Veristat for regulatory approval of the therapy.PR NewswirePAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation SchedulePAO Group, Inc. confirmed plans to publish a multimedia presentation on February 16, 2021 outlining its strategy to expand into the nutraceutical market and advance CBD pharmaceutical developments for chronic obstructive pulmonary disorder (COPD) treatment. The company acquired RespRx, a cannabis-based COPD treatment, from Kali-Extracts and has partnered with the Puerto Rico Consortium for Clinical Investigation to develop proprietary CBD extract into a nutraceutical product. PAOG also disclosed a $300,000 sales agreement with anticipated quarterly revenue of $50,000 over six quarters, and engaged Alkame Holdings as copacker and North American Cannabis Holdings as distributor for its planned CBD nutraceuticals.PR NewswirePAOG Takes Next Step To Produce Cannabis NutraceuticalsPAO Group, Inc. announced it is moving forward with producing cannabis nutraceuticals for Chronic Obstructive Pulmonary Disorder (COPD) by engaging the Puerto Rico Consortium for Clinical Investigation to develop its proprietary CBD extract. The company plans to collaborate with Alkame Holdings, Inc. for the packaging of these products, building on its previous acquisition of the RespRx treatment from Kali-Extracts, Inc.PR NewswirePAOG Sets 2021 Cannabis Biopharmaceutical Revenue GoalsPAO Group, Inc. published its 2021 strategic outlook for its cannabis biopharmaceutical assets, which include RespRx and a hemp cultivation business acquired from Kali-Extracts and Puration, respectively. The company has engaged Veristat and the Puerto Rico Consortium for Clinical Investigation to advance clinical development and nutraceutical initiatives for COPD treatments while planning a new facility in Texas with partners PURA and Alkame Holdings. Additionally, PAOG announced an application to issue stock dividends to PURA shareholders as part of the acquisition terms.PR NewswirePAOG Publishes Q3 RPT Including PURA And KALY Acquisitions - Now One Key Step Closer To Dividend DistributionPAO Group, Inc. (PAOG) published its Q3 2020 report with OTC Markets, marking its first report since completing two strategic acquisitions in the quarter: a cannabis extraction technology called RespRx from Kali-Extracts (KALY) and a cannabis cultivation operation from Puration, Inc. (PURA). The company expects to sell existing inventory from the cultivation acquisition in Q4 and stated that integrating these acquisitions advances a planned dividend distribution of PAOG stock to PURA shareholders at a ratio of one PAOG share for every PURA share owned.PR NewswirePAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory ApprovalPAOG Group, Inc. announced executing a master services agreement with a clinical research organization to prepare for initiating an Investigational New Drug application with the FDA for RespRx, a cannabis treatment for Chronic Obstructive Pulmonary Disease. The year-long CRO agreement represents a major step toward advancing RespRx through the regulatory approval process, with a joint announcement planned for the following week. Less than 90 days prior, PAOG acquired RespRx from Kali-Extracts and separately acquired a hemp cultivation business from Puration, with both acquisitions now being integrated into the company's pharmaceutical development operations.PR NewswirePAOG - New Independent CBD Research Appears To Support PAOG RespRx ResearchPAO Group, Inc. acquired RespRx, a cannabis-based treatment for Chronic Obstructive Pulmonary Disease under development from a patented extraction method, from Kali-Extracts in July 2020. The company is highlighting new research published in Cannabis and Cannabinoid Research showing CBD reduced excessive lung inflammation and improved lung function in COVID-19 models, which it claims supports its RespRx development program. PAOG announced plans to release a key update on advancing an Investigational New Drug application with the FDA and anticipates entering an agreement with a contract research organization to progress the treatment toward approval.PR NewswirePAOG Advances Independent Research of Cannabis Drug RespRxPAO Group, Inc. is advancing independent research into its cannabis drug RespRx for COPD treatment following its acquisition of the asset from Kali-Extracts, Inc., with plans to engage a contract research organization for an investigational New Drug application. The company also partnered with Puration, Inc. to expand hemp cultivation operations in Farmersville, Texas, aiming to develop proprietary cultivars to support current and future pharmaceutical developments.